189 related articles for article (PubMed ID: 34088723)
1. An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer.
Bai Y; Cole K; Martinez-Morilla S; Ahmed FS; Zugazagoitia J; Staaf J; Bosch A; Ehinger A; Nimeus E; Hartman J; Acs B; Rimm DL
Clin Cancer Res; 2021 Oct; 27(20):5557-5565. PubMed ID: 34088723
[TBL] [Abstract][Full Text] [Related]
2. An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.
Xirou V; Moutafi M; Bai Y; Nwe Aung T; Burela S; Liu M; Kimple RJ; Shabbir Ahmed F; Schultz B; Flieder D; Connolly DC; Psyrri A; Burtness B; Rimm DL
Oral Oncol; 2024 May; 152():106750. PubMed ID: 38547779
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Leon-Ferre RA; Jonas SF; Salgado R; Loi S; de Jong V; Carter JM; Nielsen TO; Leung S; Riaz N; Chia S; Jules-Clément G; Curigliano G; Criscitiello C; Cockenpot V; Lambertini M; Suman VJ; Linderholm B; Martens JWM; van Deurzen CHM; Timmermans AM; Shimoi T; Yazaki S; Yoshida M; Kim SB; Lee HJ; Dieci MV; Bataillon G; Vincent-Salomon A; André F; Kok M; Linn SC; Goetz MP; Michiels S;
JAMA; 2024 Apr; 331(13):1135-1144. PubMed ID: 38563834
[TBL] [Abstract][Full Text] [Related]
4. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
Gao G; Wang Z; Qu X; Zhang Z
BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.
Dieci MV; Criscitiello C; Goubar A; Viale G; Conte P; Guarneri V; Ficarra G; Mathieu MC; Delaloge S; Curigliano G; Andre F
Ann Oncol; 2014 Mar; 25(3):611-618. PubMed ID: 24401929
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Assessment of Tumor-Infiltrating Lymphocytes Using Machine Learning Predicts Survival in Muscle-Invasive Bladder Cancer.
Zheng Q; Yang R; Ni X; Yang S; Jiao P; Wu J; Xiong L; Wang J; Jian J; Jiang Z; Wang L; Chen Z; Liu X
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498655
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic Prognostic Impact of Tumor-infiltrating Lymphocytes in Systemically Untreated Patients With Early-stage Triple-negative Breast Cancer.
Park JH; Lee HJ; Lee SB; Ahn JH; Kim JE; Jung KH; Gong G; Son BH; Ahn SH; Kim SB
Anticancer Res; 2019 Jun; 39(6):3111-3119. PubMed ID: 31177156
[TBL] [Abstract][Full Text] [Related]
11. Correlation Between MRI and the Level of Tumor-Infiltrating Lymphocytes in Patients With Triple-Negative Breast Cancer.
Ku YJ; Kim HH; Cha JH; Shin HJ; Baek SH; Lee HJ; Gong G
AJR Am J Roentgenol; 2016 Nov; 207(5):1146-1151. PubMed ID: 27556407
[TBL] [Abstract][Full Text] [Related]
12. An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma.
Acs B; Ahmed FS; Gupta S; Wong PF; Gartrell RD; Sarin Pradhan J; Rizk EM; Gould Rothberg B; Saenger YM; Rimm DL
Nat Commun; 2019 Nov; 10(1):5440. PubMed ID: 31784511
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
BMC Cancer; 2021 Mar; 21(1):286. PubMed ID: 33726701
[TBL] [Abstract][Full Text] [Related]
14. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Lee J; Kim DM; Lee A
Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
[TBL] [Abstract][Full Text] [Related]
16. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
[TBL] [Abstract][Full Text] [Related]
17. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.
Loi S; Michiels S; Adams S; Loibl S; Budczies J; Denkert C; Salgado R
Ann Oncol; 2021 Oct; 32(10):1236-1244. PubMed ID: 34311075
[TBL] [Abstract][Full Text] [Related]
18. Hot Spot and Whole-Tumor Enumeration of CD8
McIntire PJ; Irshaid L; Liu Y; Chen Z; Menken F; Nowak E; Shin SJ; Ginter PS
Clin Breast Cancer; 2018 Dec; 18(6):451-458.e1. PubMed ID: 29866579
[TBL] [Abstract][Full Text] [Related]
19. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer.
Jimenez JE; Abdelhafez A; Mittendorf EA; Elshafeey N; Yung JP; Litton JK; Adrada BE; Candelaria RP; White J; Thompson AM; Huo L; Wei P; Tripathy D; Valero V; Yam C; Hazle JD; Moulder SL; Yang WT; Rauch GM
Eur J Radiol; 2022 Apr; 149():110220. PubMed ID: 35193025
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
